Technical Analysis for QNCX - Quince Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.91 | -1.09% | -0.01 |
Earnings due: May 13
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Lower Bollinger Band Walk | Weakness | -1.09% | |
Stochastic Reached Oversold | Weakness | -1.09% | |
Below Lower BB | Weakness | -1.09% |
Alert | Time |
---|---|
Possible NR7 | about 13 hours ago |
Fell Below Lower Bollinger Band | about 14 hours ago |
Fell Below Previous Day's Low | about 14 hours ago |
Down 2 % | about 14 hours ago |
60 Minute Opening Range Breakdown | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
Quince Therapeutics, Inc. Description
Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Organ Systems Rare Diseases Bone Acute Pain Skeletal Disorders Skeletal System Bone Fracture Musculoskeletal System Osteogenesis Imperfecta
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.74 |
52 Week Low | 0.84 |
Average Volume | 76,929 |
200-Day Moving Average | 1.13 |
50-Day Moving Average | 1.09 |
20-Day Moving Average | 1.01 |
10-Day Moving Average | 0.99 |
Average True Range | 0.08 |
RSI (14) | 35.06 |
ADX | 19.2 |
+DI | 10.43 |
-DI | 20.02 |
Chandelier Exit (Long, 3 ATRs) | 0.89 |
Chandelier Exit (Short, 3 ATRs) | 1.12 |
Upper Bollinger Bands | 1.12 |
Lower Bollinger Band | 0.91 |
Percent B (%b) | 0.02 |
BandWidth | 21.02 |
MACD Line | -0.04 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0089 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.96 | ||||
Resistance 3 (R3) | 0.96 | 0.95 | 0.95 | ||
Resistance 2 (R2) | 0.95 | 0.94 | 0.95 | 0.95 | |
Resistance 1 (R1) | 0.93 | 0.93 | 0.93 | 0.93 | 0.95 |
Pivot Point | 0.91 | 0.91 | 0.91 | 0.91 | 0.91 |
Support 1 (S1) | 0.90 | 0.90 | 0.89 | 0.89 | 0.87 |
Support 2 (S2) | 0.88 | 0.89 | 0.88 | 0.87 | |
Support 3 (S3) | 0.86 | 0.88 | 0.87 | ||
Support 4 (S4) | 0.86 |